AML Revenue and Competitors

Location

N/A

Total Funding

3D

Industry

Estimated Revenue & Valuation

  • AML's estimated annual revenue is currently $6M per year.(i)
  • AML's estimated revenue per employee is $136,000

Employee Data

  • AML has 44 Employees.(i)
  • AML grew their employee count by -19% last year.

AML's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Technology OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6M44-19%N/AN/A
#2
$1.3M130%N/AN/A
#3
$16.3M969%N/AN/A
#4
$0.4M5N/AN/AN/A
#5
$2932.2M123206%N/AN/A
#6
$0.5M138%$5MN/A
#7
$1.4M140%N/AN/A
#8
$88.2M4158%N/AN/A
#9
$5.7M4214%N/AN/A
#10
$331.6M13644%$3.5BN/A
Add Company

What Is AML?

AML IS THE “WORLD'S BEST” AT OPTIMIZING MAGNET-BASED APPLICATIONS Unlike any other company, AML offers a total, end-to-end capability that brings together advanced technologies, skills and specialized knowledge sharply focused on the commercialization of high-performance magnetics. With our Perfect-FieldTM Application Development Process at its heart, our layered intellectual property portfolio is comprised of dozens of existing and pending patents that cover hundreds of discrete technologies and capabilities. It also encompasses dozens of strategic partners, as well as an impressive list of international science projects, laboratories, universities, foundations and government agencies. AML'S MARKET EXPERIENCE IS DIVERSE Energy Medical eMobility Space Oil & Gas Research Superconductivity

keywords:N/A

N/A

Total Funding

44

Number of Employees

$6M

Revenue (est)

-19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AML News

2022-04-20 - OCC Found Anchorage Failed to Maintain Proper AML Rules

According to a consent order, in which Anchorage neither admits nor denies the OCC's findings, the company has to appoint a compliance...

2022-04-20 - Astellas Announces Reimbursement for XOSPATA® (gilteritinib) in Most Provinces for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed or refractory acute myeloid...

2022-04-20 - OCC’s Rule on SARs May Boost Innovation on AML Reporting

On May 1, a new rule issued by the OCC that modifies the requirements for national banks and federal savings associations to file SARs will...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.1M44-12%N/A
#2
$5.1M44N/AN/A
#3
$8.4M44-25%N/A
#4
$15M440%N/A
#5
$11.6M4416%N/A